Arrowhead Q3 revenue $75.3M; plozasiran Phase 3 hits endpoints; Madrigal license deal

ARROWHEAD PHARMACEUTICALS, INC.

2026-Q3 EPS reported -$2.10 revenue$413,023,000

Revenue $75.3M (up 171% YoY); net loss $194.3M ($1.36 diluted EPS) vs $175.2M ($1.26) prior year.
Plozasiran Phase 3 SHASTA-3/4: 79% and 81% median triglyceride reductions; 78% reduction in acute pancreatitis events.
Acquired FDA priority review voucher for plozasiran sNDA in sHTG, expected before end of 2026.
Exclusive license to Madrigal for ARO-PNPLA3: $25M upfront, up to $975M milestones, tiered royalties.
REDEMPLO prescriptions roughly doubled in Q3; >400 prescribers; EU and Australia marketing authorizations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.